Literature DB >> 28947610

Regulating protein breakdown through proteasome phosphorylation.

Jordan J S VerPlank1, Alfred L Goldberg2.   

Abstract

The ubiquitin proteasome system degrades the great majority of proteins in mammalian cells. Countless studies have described how ubiquitination promotes the selective degradation of different cell proteins. However, there is a small but the growing literature that protein half-lives can also be regulated by post-translational modifications of the 26S proteasome. The present study reviews the ability of several kinases to alter proteasome function through subunit phosphorylation. For example, PKA (protein kinase A) and DYRK2 (dual-specificity tyrosine-regulated kinase 2) stimulate the proteasome's ability to degrade ubiquitinated proteins, peptides, and adenosine triphosphate, while one kinase, ASK1 (apoptosis signal-regulating kinase 1), inhibits proteasome function during apoptosis. Proteasome phosphorylation is likely to be important in regulating protein degradation because it occurs downstream from many hormones and neurotransmitters, in conditions that raise cyclic adenosine monophosphate or cyclic guanosine monophosphate levels, after calcium influx following synaptic depolarization, and during phases of the cell cycle. Beyond its physiological importance, pharmacological manipulation of proteasome phosphorylation has the potential to combat various diseases. Inhibitors of phosphodiesterases by activating PKA or PKG (protein kinase G) can stimulate proteasomal degradation of misfolded proteins that cause neurodegenerative or myocardial diseases and even reduce the associated pathology in mouse models. These observations are promising since in many proteotoxic diseases, aggregation-prone proteins impair proteasome function, and disrupt protein homeostasis. Conversely, preventing subunit phosphorylation by DYRK2 slows cell cycle progression and tumor growth. However, further research is essential to determine how phosphorylation of different subunits by these (or other) kinases alters the properties of this complex molecular machine and thus influence protein degradation rates.
© 2017 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  proteasome activation; proteasome phosphorylation; protein degradation; protein homeostasis; protein kinase; ubiquitin proteasome system

Mesh:

Substances:

Year:  2017        PMID: 28947610      PMCID: PMC5831125          DOI: 10.1042/BCJ20160809

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  99 in total

Review 1.  Protein degradation and protection against misfolded or damaged proteins.

Authors:  Alfred L Goldberg
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

2.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.

Authors:  Natura Myeku; Catherine L Clelland; Sheina Emrani; Nikolay V Kukushkin; Wai Haung Yu; Alfred L Goldberg; Karen E Duff
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

Review 3.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 4.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 5.  When Worlds Collide-Mechanisms at the Interface between Phosphorylation and Ubiquitination.

Authors:  Pavel Filipčík; Jack R Curry; Peter D Mace
Journal:  J Mol Biol       Date:  2017-02-21       Impact factor: 5.469

Review 6.  Design principles of a universal protein degradation machine.

Authors:  Mary E Matyskiela; Andreas Martin
Journal:  J Mol Biol       Date:  2012-11-09       Impact factor: 5.469

7.  Calcineurin stimulates the expression of inflammatory factors in RAW 264.7 cells by interacting with proteasome subunit alpha type 6.

Authors:  Wen Zhang; Qun Wei
Journal:  Biochem Biophys Res Commun       Date:  2011-03-21       Impact factor: 3.575

8.  Regulation of the CUL3 Ubiquitin Ligase by a Calcium-Dependent Co-adaptor.

Authors:  Colleen A McGourty; David Akopian; Carolyn Walsh; Amita Gorur; Achim Werner; Randy Schekman; Diana Bautista; Michael Rape
Journal:  Cell       Date:  2016-10-06       Impact factor: 41.582

9.  Disease-associated prion protein oligomers inhibit the 26S proteasome.

Authors:  Mark Kristiansen; Pelagia Deriziotis; Derek E Dimcheff; Graham S Jackson; Huib Ovaa; Heike Naumann; Anthony R Clarke; Fijs W B van Leeuwen; Victoria Menéndez-Benito; Nico P Dantuma; John L Portis; John Collinge; Sarah J Tabrizi
Journal:  Mol Cell       Date:  2007-04-27       Impact factor: 17.970

10.  Enhancement of proteasome activity by a small-molecule inhibitor of USP14.

Authors:  Byung-Hoon Lee; Min Jae Lee; Soyeon Park; Dong-Chan Oh; Suzanne Elsasser; Ping-Chung Chen; Carlos Gartner; Nevena Dimova; John Hanna; Steven P Gygi; Scott M Wilson; Randall W King; Daniel Finley
Journal:  Nature       Date:  2010-09-09       Impact factor: 49.962

View more
  44 in total

Review 1.  Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Authors:  Barry Boland; Wai Haung Yu; Olga Corti; Bertrand Mollereau; Alexandre Henriques; Erwan Bezard; Greg M Pastores; David C Rubinsztein; Ralph A Nixon; Michael R Duchen; Giovanna R Mallucci; Guido Kroemer; Beth Levine; Eeva-Liisa Eskelinen; Fanny Mochel; Michael Spedding; Caroline Louis; Olivier R Martin; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

2.  Specific lid-base contacts in the 26s proteasome control the conformational switching required for substrate degradation.

Authors:  Eric R Greene; Ellen A Goodall; Andres H de la Peña; Mary E Matyskiela; Gabriel C Lander; Andreas Martin
Journal:  Elife       Date:  2019-11-28       Impact factor: 8.140

3.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

4.  Reversible phosphorylation of Rpn1 regulates 26S proteasome assembly and function.

Authors:  Xiaoyan Liu; Weidi Xiao; Yanan Zhang; Sandra E Wiley; Tao Zuo; Yingying Zheng; Natalie Chen; Lu Chen; Xiaorong Wang; Yawen Zheng; Lan Huang; Shixian Lin; Anne N Murphy; Jack E Dixon; Ping Xu; Xing Guo
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

Review 5.  Proteasome Biology: Chemistry and Bioengineering Insights.

Authors:  Lucia Račková; Erika Csekes
Journal:  Polymers (Basel)       Date:  2020-12-04       Impact factor: 4.329

6.  Proteasome regulation by reversible tyrosine phosphorylation at the membrane.

Authors:  Lu Chen; Yanan Zhang; Xin Shu; Qiong Chen; Tiantian Wei; Heman Wang; Xiaorong Wang; Qirou Wu; Xiaomei Zhang; Xiaoyan Liu; Suya Zheng; Lan Huang; Junyu Xiao; Chao Jiang; Bing Yang; Zhiping Wang; Xing Guo
Journal:  Oncogene       Date:  2021-02-18       Impact factor: 9.867

7.  ZFAND5/ZNF216 is an activator of the 26S proteasome that stimulates overall protein degradation.

Authors:  Donghoon Lee; Shinichi Takayama; Alfred L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-25       Impact factor: 11.205

Review 8.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

9.  Proteins containing ubiquitin-like (Ubl) domains not only bind to 26S proteasomes but also induce their activation.

Authors:  Galen A Collins; Alfred L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-18       Impact factor: 11.205

Review 10.  The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Brian J North; Kaixiong Tao; Pengbo Zhou; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-12-30       Impact factor: 10.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.